SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Interest Expense

Cost of servicing the company's debt during the period.

SIGA Technologies, Inc.NASDAQ: SIGA

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for SIGA, versus a peer median of 5.3%.
SIGA Competitors
Interest Expense for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$55.6M USD-9.4%+16.7%8.2%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$45.38M USD-29.8%+14.2%10.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.76M USD-0.8%+11.2%33.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$6.9M USD-12.6%+25.5%2.3%
SNDLSNDL Inc.LTM Mar 2026CA$5.69M CAD-24.9%+8.4%0.6%
DRIODarioHealth Corp.LTM Mar 2026$4.5M USD+3844.7%+7.8%21.2%
SIGASIGA Technologies, Inc.LTM Mar 2026$0 USD——0.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding SIGA) —-12.6%+12.7%5.3%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.